89bio Email Format
Biotechnology ResearchCalifornia, United States51-200 Employees
89bio was acquired by Roche in September 2025, making the company a member of the Roche Group. We look forward to advancing our innovative FGF21 analog, pegozafermin, as part of Roche’s Pharmaceuticals Division and continuing our mission to help patients with serious liver and cardiometabolic diseases. Pegozafermin is currently being evaluated in Phase 3 trials for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).